title: Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
authors.affiliation: Department of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
authors.forename: Ario
authors.initials: A
authors.lastname: Takeuchi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Eto
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tatsugami
authors.forename: Hisakata
authors.initials: H
authors.lastname: Yamada
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Oki
authors.forename: Keijiro
authors.initials: K
authors.lastname: Kiyoshima
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Yoshikai
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007155:Immunologic Factors; D016898:Interferon-alpha; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib